253 related articles for article (PubMed ID: 33469292)
41. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
42. Metal based nanoparticles as cancer antigen delivery vehicles for macrophage based antitumor vaccine.
Chattopadhyay S; Dash SK; Mandal D; Das B; Tripathy S; Dey A; Pramanik P; Roy S
Vaccine; 2016 Feb; 34(7):957-67. PubMed ID: 26772632
[TBL] [Abstract][Full Text] [Related]
43. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
44. Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
Du JJ; Zou SY; Chen XZ; Xu WB; Wang CW; Zhang L; Tang YK; Zhou SH; Wang J; Yin XG; Gao XF; Liu Z; Guo J
Chem Asian J; 2019 Jun; 14(12):2116-2121. PubMed ID: 31042017
[TBL] [Abstract][Full Text] [Related]
45. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
46. Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice.
Ma XJ; Tian DY; Xu D; Yang DF; Zhu HF; Liang ZH; Zhang ZG
World J Gastroenterol; 2007 Feb; 13(7):1060-6. PubMed ID: 17373740
[TBL] [Abstract][Full Text] [Related]
47. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo.
Zhu H; Wang K; Wang Z; Wang D; Yin X; Liu Y; Yu F; Zhao W
Acta Biomater; 2022 Jan; 138():491-504. PubMed ID: 34757230
[TBL] [Abstract][Full Text] [Related]
48. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.
Roulois D; Grégoire M; Fonteneau JF
Biomed Res Int; 2013; 2013():871936. PubMed ID: 23509794
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
50. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
Gao FS; Zhan YT; Wang XD; Zhang C
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
52. Anti-tumor immunostimulatory effect of heat-killed tumor cells.
Yoon TJ; Kim JY; Kim H; Hong C; Lee H; Lee CK; Lee KH; Hong S; Park SH
Exp Mol Med; 2008 Feb; 40(1):130-44. PubMed ID: 18305406
[TBL] [Abstract][Full Text] [Related]
53. Multifunctional Lipidated Protein Carrier with a Built-In Adjuvant as a Universal Vaccine Platform Potently Elevates Immunogenicity of Weak Antigens.
Zhou SH; Zhang RY; Wen Y; Zou YK; Ding D; Bian MM; Cui HY; Guo J
J Med Chem; 2024 Apr; 67(8):6822-6838. PubMed ID: 38588468
[TBL] [Abstract][Full Text] [Related]
54. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
55. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
56. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
[TBL] [Abstract][Full Text] [Related]
57. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
58. Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy.
Ahn S; Lee IH; Kang S; Kim D; Choi M; Saw PE; Shin EC; Jon S
Adv Healthc Mater; 2014 Aug; 3(8):1194-9. PubMed ID: 24652754
[TBL] [Abstract][Full Text] [Related]
59. Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects.
Zhang S; Liu Y; Zhou J; Wang J; Jin G; Wang X
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499455
[TBL] [Abstract][Full Text] [Related]
60. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.
Li M; Shi H; Mu Y; Luo Z; Zhang H; Wan Y; Zhang D; Lu L; Men K; Tian Y; Wu X; Liu X; Pan Y; Fan Y; Yu C; Zhou B; Xiang R; Chen X; Yang L
Mol Cancer; 2014 Jul; 13():179. PubMed ID: 25070035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
